Your browser is no longer supported. Please, upgrade your browser.
Settings
FMTX [NASD]
Forma Therapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-1.97 Insider Own0.70% Shs Outstand42.38M Perf Week-9.21%
Market Cap1.32B Forward P/E- EPS next Y-3.67 Insider Trans0.00% Shs Float40.36M Perf Month-18.21%
Income-74.20M PEG- EPS next Q-0.77 Inst Own83.90% Short Float14.10% Perf Quarter-32.92%
Sales- P/S- EPS this Y-120.20% Inst Trans36.52% Short Ratio11.20 Perf Half Y-49.66%
Book/sh15.30 P/B1.64 EPS next Y-16.50% ROA-16.60% Target Price- Perf Year-
Cash/sh12.10 P/C2.08 EPS next 5Y- ROE-19.40% 52W Range22.51 - 56.33 Perf YTD-27.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.35% Beta-
Dividend %- Quick Ratio20.60 Sales past 5Y- Gross Margin- 52W Low11.73% ATR2.25
Employees103 Current Ratio20.60 Sales Q/Q- Oper. Margin- RSI (14)36.02 Volatility6.92% 9.05%
OptionableYes Debt/Eq0.00 EPS Q/Q53.80% Profit Margin- Rel Volume0.96 Prev Close24.97
ShortableYes LT Debt/Eq0.00 EarningsMar 30 BMO Payout- Avg Volume508.07K Price25.15
Recom1.50 SMA20-9.48% SMA50-24.80% SMA200-36.00% Volume484,286 Change0.72%
Mar-31-21Reiterated H.C. Wainwright Buy $53 → $55
Feb-17-21Initiated Oppenheimer Outperform $60
Sep-08-20Initiated H.C. Wainwright Buy $53
Jul-14-20Initiated SVB Leerink Outperform $54
Jul-14-20Initiated Jefferies Buy $54
Jul-14-20Initiated Credit Suisse Outperform $64
Mar-30-21 11:08AM  
07:20AM  
07:05AM  
06:15AM  
Mar-23-21 04:05PM  
Mar-03-21 08:50AM  
Feb-17-21 07:05AM  
Jan-20-21 07:05AM  
Jan-11-21 07:05AM  
Jan-07-21 07:05AM  
Dec-19-20 03:11AM  
Dec-15-20 04:35PM  
Dec-10-20 10:53PM  
06:34PM  
Dec-08-20 04:15PM  
Dec-07-20 04:30PM  
Nov-12-20 07:05AM  
Nov-10-20 07:05AM  
Nov-04-20 01:11PM  
07:05AM  
Oct-26-20 07:05AM  
Sep-20-20 10:40AM  
Sep-15-20 07:05AM  
Sep-09-20 07:05AM  
Aug-13-20 07:05AM  
Jul-30-20 07:05AM  
Jul-02-20 07:30PM  
Jun-23-20 04:05PM  
Jun-18-20 09:04PM  
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Potts JeannetteSee RemarksDec 30Option Exercise5.053,40017,1703,400Jan 08 04:03 PM